Badanie nad bezpieczeństwem i skutecznością BCN-CP01 u pacjentów z przewlekłą białaczką limfocytową lub chłoniakiem limfocytowym

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are types of blood cancers that affect a kind of white blood cell called lymphocytes. These diseases can sometimes return or not respond to treatment, which is known as being "relapsed" or "refractory." The study is looking at a new treatment called BCN-CP01, which is a type of cell therapy. This treatment involves using a patient's own T cells, a type of immune cell, that are modified to better fight cancer cells. The modification targets a protein called CD19 found on the surface of cancer cells.

The purpose of the study is to check how safe and effective BCN-CP01 is for people with relapsed or refractory CLL or SLL. The study is divided into two parts. The first part focuses on understanding the safety of the treatment and finding the right dose. The second part looks at how well the treatment works in reducing cancer. Participants will receive the treatment through an infusion, which means it is given directly into the bloodstream.

During the study, participants will be monitored for any side effects and to see how their cancer responds to the treatment. The study aims to provide more information on whether this new approach can be a helpful option for people with these types of blood cancers. A placebo may be used in some parts of the study to compare results. The study is expected to continue until 2026.